Microbiota in health and disease

Overview

The gut microbiota - the trillions of bacteria, archaea, fungi, and viruses colonising the GI tract - performs essential metabolic, immune, and barrier functions, and its disruption ("dysbiosis") is increasingly implicated in a wide range of GI and systemic disease
An area of rapidly expanding clinical relevance, though the field is still maturing from largely associative evidence toward a smaller number of clinically actionable, causally-established interventions

Normal microbiota ferments non-digestible carbohydrate to short-chain fatty acids (butyrate, propionate, acetate) - butyrate specifically is the primary energy source for colonocytes and has anti-inflammatory effects on the gut mucosa
The microbiota also provides colonisation resistance against pathogenic organisms (competing for nutrients/attachment sites) and contributes to normal immune system development/regulation via ongoing low-level immune signalling

Dysbiosis is implicated (with varying strength of evidence) in inflammatory bowel disease, irritable bowel syndrome, Clostridioides difficile infection (the clearest, most causally established example - loss of colonisation resistance after antibiotic-driven dysbiosis directly permits C. difficile overgrowth), obesity/metabolic syndrome, and even some non-GI conditions via the "gut-brain axis" and other proposed systemic pathways
Microbiota composition is highly individual and influenced by diet, antibiotic exposure, mode of birth delivery, and other environmental factors - making population-level generalisations about a "healthy" microbiota profile difficult to define precisely

Faecal microbiota transplantation (FMT) has robust evidence specifically for *recurrent C. difficile infection*, where it directly restores colonisation resistance - the clearest, most established clinical application of microbiota manipulation
Probiotic use for other indications (IBS, general gut health) has more mixed, strain- and indication-specific evidence, and should not be assumed to have the same evidence strength as FMT for recurrent C. difficile
Antibiotic stewardship (minimising unnecessary antibiotic exposure) is itself a microbiota-preserving intervention with broad relevance across GI and infectious disease practice

Recurrent Clostridioides difficile infection (FMT indication), inflammatory bowel disease, irritable bowel syndrome, antibiotic-associated diarrhoea
FMT for recurrent C. difficile infection is the clearest example of translating microbiota science into an established, effective clinical treatment - most other proposed microbiota-disease associations remain at an earlier stage of evidence, and should be distinguished from this well-established application when counselling patients

4 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.